ATP and its metabolites are potent autocrine agonists that act extracellularly within tissues to affect epithelial function. In polycystic kidneys, renal tubules become dilated and/or encapsulated as cysts, creating abnormal microenvironments for autocrine signaling. Previously, our laboratory has shown that high nanomolar to micromolar quantities of ATP are released from cell monolayers in vitro and detectable in cyst fluids from microdissected human autosomal dominant polycystic kidney (ADPKD) cysts. Here, we show enhanced ATP release and ATP release dysregulation from autosomal recessive polycystic kidney (ARPKD) and ADPKD epithelial cell models. RT-PCR and immunoblotting for P2Y G protein-coupled receptors and P2X purinergic receptor channels show expression of mRNA and/or protein for multiple subtypes from both families. Assays of cytosolic Ca 2+ and secretory Cl -transport shows P2Y and P2X purinergic receptor-mediated stimulation of Cl -secretion via cytosolic Ca 2+ -dependent signaling. Therefore, we hypothesize that autocrine purinergic signaling may augment detrimentally cyst volume expansion in ADPKD or tubule dilation in ARPKD, accelerating disease progression.
Introduction
Polycystic kidney disease (PKD) exists in at least two genetic forms, autosomal recessive (ARPKD) and autosomal dominant (ADPKD), that can be affected further by additional modifier genes {43}. In both forms, tubules are altered in their architecture, leading to dilated tubules or cysts encapsulated by a single monolayer of renal epithelia {43}. This abnormal structure creates abnormal microenvironments in which autocrine and paracrine agonists such as growth factors, nucleotides, and inflammatory mediators could affect cystic epithelial function abnormally.
Recently, our laboratory showed that ATP is also present in high nanomolar to micromolar quantities in fluids extracted from the interior of a subset of ADPKD cysts, the abnormal microenvironment alluded to above {50}. Nucleotides in extracellular fluid act as autocrine and paracrine hormones to regulate a variety of physiological processes under normal physiological conditions {1, 28, 14, 38, 39}. Nucleotides inhibit Na + absorption and stimulate Cl -secretion across epithelia derived from airway, gastrointestinal, and other tissues {10, 17, 21, 37}.
Recently, McCoy et al. {30} found that nucleotide agonists stimulate Cl -secretion and inhibit Na + absorption in an inner medullary collecting duct (IMCD) cell line (mIMCD-K2). Kishore and coworkers have shown that ATP and UTP inhibit vasopressin-induced water flow across IMCD {22, 23}. Once released from cells, nucleotides activate purinoceptors that are divided into two classes: P1 (activated by adenosine) and P2 (activated by ATP and ADP){1, 28, 38, 39}.
P2 purinoceptors have been subdivided into two families, P2X and P2Y. The P2X purinoceptor family contains at least eight distinct subtypes (P2X1 through P2X7 and P2XM), each of which is a two transmembrane-spanning, ion channel-forming protein {1, 28, 38, 39}. Ionotropic P2X receptor channels bind ATP and form Ca 2+ -permeable, non-selective cation channels which, when activated, increase intracellular Ca 2+ {1, 28, 38, 39}. The P2Y purinoceptor family is a seven transmembrane-spanning, G-protein-coupled, metabotropic receptor family containing at At the present time, the existence of P2 receptors in PKD renal cyst epithelial cells remains unknown. Our hypothesis is that these cells do express purinergic receptors and that autocrine ATP signaling via these receptors stimulates chloride secretion in PKD. Our results provide evidence that: (1) PKD epithelial monolayers release ATP in a dynamic and regulated manner;
(2) PKD epithelial ATP release is potentiated by cytosolic calcium; (3) PKD epithelia express multiple purinergic receptor subtypes to receive that autocrine signal; (4) PKD epithelia respond to nucleotides, via purinergic receptors, with increases in cytosolic calcium; and (5) P2Y-and P2X-selective agonists stimulate chloride secretion across PKD epithelial monolayers. As such, all limbs of an autocrine extracellular purinergic signaling loop exist at the level of the PKD epithelium and may exacerbate fluid accumulation that may contribute to increased cyst size and the slow but constant progression of PKD.
Methods and Materials
ADPKD and ARPKD Cell Primary Culture: Human ADPKD epithelial primary cultures (coded "hADPKD"), human whole kidney epithelial primary cultures (coded "hRE"), and mouse collecting duct primary cultures from "B6 control" and "cpk ARPKD" mice were grown on York, NY) was grown at 32-33 o C (but never above 33 o C) in a 5% CO 2 humidified incubator in MEM with Earle's salts (Gibco-BRL) supplemented with 10% FBS (Gibco-BRL), 1X Lglutamine, 1X penicillin/streptomycin, and 1X fungizone. Once confluent, these cells (coded "ADPKD 33 o C") were subcultured onto filters and switched to a similar environment but at 37 o C to promote differentiation into a monolayer. These monolayers were tight to fluid; however, the transepithelial resistance was not sufficiently high enough to perform Ussing chamber measurements. ATP release assays, RT-PCR, and biochemistry could, however, be performed on this ADPKD cell line.
Primary Cultures of hADPKD Grown as Monolayers for Ussing Chambers:
Human ADPKD epithelial cells (hADPKD) were harvested from surface cysts of kidneys removed from four patients with ADPKD. The procedure for establishing primary cultures of ADPKD cells has been published elsewhere {29, 47}. Briefly, kidneys were removed, placed in sterile bags, and shipped on wet ice to our laboratory by overnight delivery. During dissection of the cyst wall, fibrous tissue was manually removed to reduce the amount of fibroblasts in the primary culture and to enrich the culture with epithelial cells. The dissected tissue was several times rinsed in DME/F12 containing penicillin/streptomycin, minced using sterile surgical scissors and incubated for 8 h in media containing 220 IU/ml collagenase (Type IV, Cooper Biochemical, Malvern, PA) at 37° C.
Small pieces of tissue and dispersed cells were then rinsed in DME/F12 supplemented with 5% FBS and insulin-transferrin-selenium (ITS). Cells were allowed to attach and propagate on plastic until they were harvested by trypsinization. Transport studies were performed on cells from the original primary culture or after the first passage.
Bioluminescence Detection of ATP Released from Epithelial Cell Cultures and Monolayers:
Monolayers were washed 3 times in PBS to remove any FBS present in the culture medium.
Methodology for ATP release assays has been published in detail for experiments performed on epithelial monolayers {44}.
Bioluminescence Detection of ATP Degradation by Epithelial Cell Cultures:
All details concerning this assay have been published {44}. Briefly, however, a known quantity of ATP (10 uM) was spiked into the culture medium, and aliquots of the medium were taken before and after exposure to cells at the timepoints shown. Cells were grown in flasks and studied in flasks at 37 oC, where ecto-ATPases would be maximally active. All aliquots were screened by the luciferase:luciferin assay to measure ATP-driven bioluminescence that decayed over time upon exposure to the cells.
Preparation of Total RNA for PCR:
The above cell models were grown to confluence in collagen-coated flasks, and the cells were lysed by TRIzol reagent TM DNA Sequencing of PCR Products: PCR products were isolated from agarose gel slices using a Qiaquick gel extraction kit (Qiagen). PCR products were ligated into a pGEM-T vector system (Promega) and then transformed into JM109 high efficiency competent cells (Promega).
Transformed bacteria were then plated onto LB-agar plates containing ampicillin (100 µg/ml), XGal (40 µg/ml), IPTG (100 µg/ml) for ampicillin selection of successful transformants and blue/white selection of successful PCR product ligation. White colonies were picked off the plate to inoculate a 6 ml LB growup with continued ampicillin selection. The pGEM-T plasmids with insert were purified using a PerfectPrep miniprep kit (5 Prime-3 Prime). The purified DNA was denatured in 0.2 N NaOH, precipitated in 7.5 M NH 4 Cl and 100% ethanol, and sequenced using Sequenase TM dideoxy termination method (Amersham/US Biochemicals) using α- Immunoblotting with P2X Receptor Channel Isoform-Specific Antibodies: Cells were lysed in a buffer containing 10 mM Tris, 0.5 mM NaCl, 0.5% Triton X-100, 50 µg/ml aprotinin (Sigma, St.
Louis, MO), 100 µg/ml leupeptin (Sigma), and 100 µg/ml pepstatin A (Sigma) adjusted to pH (1). R te of the ADPKD monolayers ranged from 0.1 to 1 kΩ. In electrophysiological studies, forskolin and DIDS were dissolved in ethanol and bumetanide and diphenylamine-2-carboxylate (DPC; Fluka Chemical) were dissolved in dimethyl sulfoxide as 1000X stock. The maximum % DMSO or ethanol in the preparation never exceeded 0.1%.
Data Analysis and Statistics:
In Table 1 , luminescence values (in arbitrary light units), absolute concentration of ATP, and rate of appearance of ATP in the medium are shown. As a caveat, however, all three parameters are dependent upon the three factors: (1) Table 1 shows that constitutive (basal)-and hypotonicity (or swelling)-induced ATP release was significantly greater across the apical membrane of cpk mouse collecting duct epithelial monolayers versus B6 controls. The luminescence difference was even greater if the data are separated in the cpk group between monolayers where "domes" (tubule-or cyst-like) structures were visibly emerging from the monolayer versus monolayers that had no such structures (Table   1 ). It is likely that the 'domes' observed in cystic monolayers may have trapped some of the released ATP. ATP release under basal conditions was similar across the basolateral membrane of B6 and cpk monolayers; however, hypotonicity-induced ATP release was again augmented in cpk monolayers (Table 1) . ATP release is also greater in hADPKD monolayers versus the most appropriate companion control, monolayers of human whole kidney renal epithelial (hRE)
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ATP release is potentiated in ARPKD and ADPKD epithelial monolayers in vitro
monolayers. These studies show that ATP release and signaling is enhanced in the mouse ARPKD and human ADPKD epithelial models. This latter results agrees with previously published data from hADPKD monolayers compared to a panel of different normal control primary cultures from proximal tubule and kidney cortex {50}. Because DIDS is a potent blocker of ATP release, these results suggest that a transport mechanism is, at least in part, responsible for ATP release in these renal cell models.
Degradation of ATP by ecto-ATPases on the surface of renal epithelial cells is lacking in PKD epithelial models
Once released, extracellular ATP is subject to degradation. To examine this possibility, we compared the ability of normal and ADPKD cell models to degrade 10 µM ATP added to culture medium. Figure 1 shows the bioluminescence of samples of cell culture medium taken minutes and hours after addition of the ATP-containing medium, while ATP-containing medium that was not exposed to cells served as the control. In normal renal epithelial cell models, 50% of the total ATP in the medium was degraded by 20 minutes and less than 10% of the total ATP was remaining by 2 hours. Interestingly, degradation of ATP in ADPKD epithelial cell models occurred at a much slower rate. Fifty percent of the total ATP was degraded by 3 hours and approximately 10% of the ATP was remaining by 8 hours. Taken together, these results suggest that ATP released into the medium is degraded into its metabolites in both normal and PKD epithelial models; however and importantly, ATP is degraded 4-6 fold more slowly in PKD cell models, suggesting that the autocrine signal may last longer in the PKD epithelial microenvironment.
Multiple P2X and P2Y receptors are expressed in ARPKD and ADPKD renal epithelial cell lines and primary cultures
For ATP release and autocrine extracellular ATP signaling to be relevant to the pathogenesis of PKD, purinergic receptors that bind ATP as their physiologic ligand must be expressed on the PKD epithelium. Table 2 shows the results of degenerate RT-PCR analysis for the P2X purinergic receptor channel gene family and specific RT-PCR for P2Y G protein-coupled purinergic receptors (P2Y1, P2Y2, and P2Y6) in ARPKD and ADPKD epithelial cell models and their counterpart controls. Discrete PCR products of the expected size were amplified by degenerate primers for P2XRs (330 bp) and specific primers for P2Y1 (750 bp), P2Y2 (610 bp), and P2Y6 (870 bp). PCR products were excised as distinct bands, subcloned, and sequenced to confirm the identity of all amplified PCR products (data not shown). Human mixed normal and ADPKD epithelial cell samples expressed P2Y2 and P2Y6, but not P2Y1. In contrast, mouse B6
and cpk ARPKD collecting duct epithelial cell models expressed P2Y2 and P2Y1, but not P2Y6.
The latter data is consistent with published work from mIMCD-K2 cells, a mouse IMCD clonal epithelial cell line, that also showed expression of P2Y1 and P2Y2, but not P2Y6 {30}. Because degenerate RT-PCR for the P2X purinergic receptor channel gene family amplified a PCR product of the expected size, Table 3 shows the results of a more rigorous sequencing analysis of the degenerate P2X PCR products. Each product was also subcloned and transformed.
In this case, however, multiple white ampicillin-resistant colonies were sequenced to gauge the incidence of P2X receptor channel subtype sequences in a given cell model. In human ADPKD cell models, an equal incidence of P2X4 and P2X5 sequences was found. In the counterpart human mixed renal epithelial cultures, P2X4 and P2X5 were found in similarly high incidence along with multiple P2X7 sequences. In mouse collecting duct epithelial cell models, sequences from P2X3 and P2X4 (but not P2X5) were found. In addition, sequences for P2X1 and P2X2
were found more rarely (Table 3 protein as well as higher molecular weight glycosylated forms of P2X4 and P2X5 that ran at least 20 kDa higher than the predicted molecular mass of these proteins (40-50 kDa) (Fig. 2) . While P2X1, P2X2, and P2X7 were not present in these membrane protein lysates, these data show that P2X4 and P2X5 are expressed by human ADPKD epithelia. Functional assays using agonists selective for P2X receptor channels confirm expression of P2X receptor channel protein on the cell surface (see below), in particular, the apical membrane of a polarized PKD epithelium.
ATP agonists increase cytosolic calcium in cystic renal epithelial cells.
Because ATP agonists as well as both P2Y and P2X receptors increase cytosolic calcium (Ca (Fig. 3) . However, after prior stimulation with P2Y receptor agonists, P2XR-selective agonists only triggered a transient spike in calcium (Fig. 3) . In all cases, both transient and sustained components of the Ca 2+ i increase were observed in response to P2Y agonists (Fig. 3) . Reversibility with washout of the agonist was only tested when a sustained response was observed (Fig. 3) . More interesting still, a lack of desensitization in P2Y and P2X receptor-mediated Ca 
P2XR and P2Y-selective agonists stimulate secretory anion transport by hADPKD epithelia
The effect of purinergic receptor agonists on anion secretion across confluent hADPKD cell monolayers were assayed by measuring short-circuit current (I SC ) in an Ussing chamber system.
Benzamil, an amiloride derivative, was added to the apical media to inhibit Na + absorption through epithelial Na + channels. Fig. 4A shows a typical response to apical application of ATP, Bz-Bz-ATP, and UTP. Each purinergic agonist caused I SC to increase and peak approximately 1 to 2 minutes after addition. Table 4 Fig. 4B and Table 4 ). In comparison, Bz-Bz-ATP applied to the basolateral side of the monolayer failed to increase I SC . These data suggest that P2X receptor channels are expressed primarily on the apical membrane of the PKD epithelium.
To define whether increases in I SC were due primarily to secretory Cl -transport, we determined if apical ATP-induced I SC could be inhibited with Cl -transport blockers. In this study, paired hADPKD monolayers were used. Benzamil was included in the apical media of both monolayers to eliminate possible effects of ATP on Na + absorption through ENaC. The effect of ATP (10 µM) was tested on monolayers bathed either in control medium or media containing Cl -transport inhibitors. DPC (1 mM) and DIDS (50 µM), inhibitors of Cl -channels, were added to the apical medium and bumetanide (100 µM), an inhibitor of Na-K-2Cl
cotransport, was added to the basolateral medium 25 minutes prior to the addition of ATP (Fig.   5 ). In 4 pairs of monolayers, the addition of ATP increased I SC by 2.7 ± 0.6 µA/cm 2 in the control group and only 0.9 ± 0.1 µA/cm 2 (p<0.05) in the presence of the Cl -transport inhibitors. DIDS also inhibited residual sustained I SC stimulated by ATP (Fig. 5B ). These data suggest that the increase in I SC with apical application of ATP is due primarily to Cl -secretion.
Cyclic AMP-dependent Cl -secretion through apical CFTR Cl -channels has previously been shown to be a major process involved in fluid secretion by ADPKD renal cyst epithelia {16, 29,
43}. In the current study, we confirmed that ATP is working on a process that is independent of the cAMP pathway. First, the addition of ATP further increased I SC above a current stimulated initially by forskolin (data not shown). Second, the increase in I SC with apical ATP was insensitive to protein kinase A (PKA) inhibition. Pretreatment for 15 minutes with H-89 (10 µM), a PKA inhibitor, had little effect on a 10 µM apical ATP-induced increase in I SC of 2.6
µA/cm 2 , a response comparable with the response of ATP by untreated monolayers (Table 4 ). In the presence of H89, forskolin failed to increase I SC (data not shown); however, in an untreated
monolayer from the same kidney preparation, forskolin increased I SC by 3.3 µA/cm 2 . Third, pretreatment with BAPTA/AM reduced the baseline current and eliminated the peak ATP response (Fig. 6) . Finally, the application of apical DIDS (50 µM), an inhibitor of a variety of Cl -channels including the Ca 2+ -dependent Cl -channel (but not CFTR when added extracellularly), caused a rapid reduction of residual ATP-stimulated I SC to baseline level (Fig. 5B) . Taken together, these data confirm that ATP is activating a Cl -secretory process that is independent of a cAMP/PKA regulation. microenvironment. In this study, we show additional evidence for enhanced ATP release in in vitro ARPKD and ADPKD models versus relevant controls. It is also important to note that it is not absolutely necessary for ATP release and signaling to be augmented in PKD. It's mere presence in an altered microenvironment were this signaling is trapped and/or prolonged may be detrimental.
Discussion
At least three possible mechanisms explain this enhanced ATP release. First, enhanced and dysregulated ATP release may be a secondary phenotype caused by a primary defect in one or both of the polycystin gene products found in ADPKD. The PKD-2 gene product, polycystin-2, has a topology not unlike a calcium-permeable cation channel and has been hypothesized to be a unique type of ion channel that interacts with and is regulated by polycystin-1 {5, 32}. Second, be present for prolonged periods within the cyst lumen. It is tempting to speculate that ectoATPases, ecto-apyrases, and ecto-nucleotidases, normally expressed on the luminal membrane of some renal epithelia, may be lacking and/or mislocalized in PKD. In ARPKD, the tubules never close off completely; however, turbulent flow in this dilated tubule may create unstirred layers that form a microenvironment for autocrine signaling.
Knowing that purinergic agonists are present in the cyst lumen is not enough. Our molecular and functional studies show that P2Y and P2X receptors are also expressed in ARPKD and ADPKD epithelial cell models. Ussing chamber measurements of human ADPKD epithelial monolayers showed expression of P2X and P2Y receptors on the luminal or apical membrane of PKD epithelia, while P2Y receptors were also expressed functionally on the serosal or basolateral membrane. Thus, these receptors are poised to receive the autocrine ATP signal at both membranes, and they need not be mislocalized. Because they are expressed naturally in this modified nephron architecture, purinergic receptors and signaling may be detrimental in PKD, without trying to be detrimental.
These results agree with several other recent studies that show concomitant expression of P2X and P2Y receptors in the same renal epithelial cell model. In a study performed in part by authors of this study, P2X3, P2X4, P2Y1, and P2Y2 receptors were found in an mIMCD-K2 cell line derived from inner medullary collecting duct {30}. Interestingly, this agrees with the purinergic receptor expression in the mouse B6 and cpk collecting duct models. With regard to in vitro cell lines and primary cultures derived from defined nephron segments, collecting duct models are the point along the nephron where P2Y and P2X expression changes. For example, up to the collecting duct, P2X4 and P2X5 are abundant. In the collecting duct, this changes to P2X3 and P2X4. This is borne out in our data in Table 3 that shows P2X4 and P2X5 in heterogeneous In summary, this study suggests strongly that extracellular purinergic signaling, via sustained increases in cytosolic Ca Possible cell biological maneuvers should be explored that interfere with purinergic signaling (ATP or adenosine scavengers, P2 and P1 purinergic receptor antagonists, inhibitors of ATP release); these agents may have therapeutic benefit by slowing the progression of PKD once cyst formation has begun. Because it is difficult to deliver any therapeutic agent to the lumen of an ADPKD cyst or a dilated ARPKD tubule, delivery before these structures have formed may be prudent. Small molecule screening for inhibitors of ATP release is also a viable option. Genetic cross of purinergic receptor knockout mice with PKD mouse models should also be considered. hADPKD primary cells grown in dishes are a more precise measure of ATP that may be released by a large cyst, while cells grown on filters are done as a microassay. This preparation had a constitutive or basal ATP release of 1773 ± 218 ALU, which corresponded to an absolute ATP concentration of 45 nM and a rate of appearance of ATP in the medium of 61.95 fM/min. With 55% hypotonicity, volume-induced ATP release was 4614 ± 662 ALU which corresponded to an absolute ATP concentration of 115 nM and a rate of appearance of ATP in the medium of 158.6 fM/min. Addition of DIDS attenuated ATP release to 127.2 ± 34.45 ALU, blocking both constitutive and swelling-induced ATP release to an absolute concentration of 5 nM and a rate of 6.895 fM/min. Table 2 Legend: *Identity of the specific P2X subtype sequences that were amplified in the degenerate RT-PR reaction are shown in Table 3 . Because RT-PCR is not quantitative, the presence or absence of an amplified band of the expected size (later verified by DNA sequencing) generated this Table. A negative result was verified by the fact that β-actin or GAPDH could be amplified from the same cDNA sample. Moreover, the same cDNA sample was used to amplify other purinergic receptor sequences shown in the Table. Table 3 Legend: *A given amplified PCR product from a cDNA sample reverse transcribed from total RNA extracted from the epithelial cell models listed above may have as many as 4 P2XR isoforms. Similar analysis was performed on epithelial cell lines and primary cultures from airway and gastrointestinal tract and from an mIMCD-K2 cell line {30, 45}. Identity of a specific P2X subtype sequence was identified via BLAST analysis using the NCBI website and the BLAST algorithm. The last number in the "Total" column is the total number of white colonies isolated and grown up to extract, purify, and sequence the pGEM-T sequencing plasmid containing the degenerate P2XR PCR product insert. Whereas no detectable signal was observed for P2X1, P2X2, or P2X7 that was the predicted size, a tight band of the expected size (45-55 kDa) as well as a broader band of higher molecular weight (65-85 kDa) was observed for P2X4. A similar phenotype was observed for P2X5. This confirmed degenerate RT-PCR data (see Table 3 ). In tunicamycin inhibition experiments (data not shown), partial elimination of the broader and higher molecular band is observed, while the tighter band of the expected size becomes more prominent. Curiously, when P2X agonists were added first, a small inhibition followed by a sustained increase in calcium was observed. However, when P2Y agonists were added, a transient spike and a sustained plateau in calcium were routinely observed. Following P2Y agonist stimulation, subsequent addition of P2X agonists caused only a transient increase in cytosolic calcium. Table 4 . For example, UTP produced a consistent stimulatory effect in K156, however it caused a variable response in K140. An ADPKD monolayer was bathed either in control media (triangle) or media containing a cocktail of Cl -transport blockers (circles) 10 min prior to adding ATP (10 µM) to the apical media. The inhibitors included apical diphenyl-2-carboxylate (DPC, 1 mM) and 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS, 50 µM) and basolateral bumetanide (100µM). Apical benzamil (10 µM) was added to the apical media prior to the experiment to reduce Na + absorption. A summary of four pairs of monolayers is included in the text. Representative experiments. P2X agonist cocktail consists of alpha,beta-methylene ATP and benzoyl-benzoyl-ATP (100 uM each); P2Y agonist cocktail consists of UTP, UDP, and ADP (100 uM each).
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Figure 3 Representative experiments. P2X agonist cocktail consists of alpha,beta-methylene ATP and benzoyl-benzoyl-ATP (100 uM each); P2Y agonist cocktail consists of UTP, UDP, and ADP (100 uM each).
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